‼️ Excited to share our new paper out now in @science.org ‼️ We describe a new tetrameric RAD51 paralog complex – XRCC3-RAD51C-RAD51D-XRCC2 – which caps the end of RAD51 filaments. Link: www.science.org/doi/epdf/10.... Thread ⬇️ (1/8)

🧬 Preprint alert! "Distinct ATRX functions cooperate with 9-1-1 and CST complexes to safeguard replication and telomere integrity." Read the manuscript here 👉 www.biorxiv.org/content/10.1...

New preprint from the lab led by @ssegurabayona.bsky.social identifying SLFN11 activity as a barrier to ALT establishment.

🚀 New preprint alert! We uncover SLFN11 as a molecular gatekeeper that restricts alternative lengthening of telomeres (ALT) by sensing telomere-associated replication stress and triggering apoptosis. 📄 Read the manuscript here: www.biorxiv.org/content/10.1...

Save de date! Join us at @cabimer.bsky.social on October 17th for the @GenomaHubCSIC Workshop in "Genome Dynamics in Development and Disease". Slots available for talks! Registration opens soon!!

We are looking to recruit three posts at the @crick.ac.uk in structural biology, cell biology, and pharmacology to join a 20+ strong multidisciplinary team focused on delivering the first precision medicines for the treatment of ALT cancers. Interested? Please check out the advertised jobs below:

Read our Q&A with Simon Boulton (@boultonlab.bsky.social), a group leader here at the Crick who co-founded the company Artios in 2016. Artios is a biotech company that develops cancer treatments that target DNA damage response pathways. www.crick.ac.uk/news-and-fea...

Artios Pharma presented data on its ATR inhibitor (blocks a key DNA damage response enzyme) at #AACR25 today. 50% response (tumor shrinkage) in patients whose tumors lacked a counterpart DNA repair enzyme called ATM. Read more in my story for @endpts.com endpts.com/artios-cance...

Exciting results were presented by Artios Pharma at the AACR meeting from their STELLA Phase 1/2a study using their ATR inhibitor ART0380 to target ATM low/negative tumours: www.artios.com/press-releas...